Image 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 8_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 6_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 7_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 8_Comparative genomics and metabolomics reveal phytohormone production, nutrient acquisition, and osmotic stress tolerance in Azotobacter chroococcum W5.xlsx by M. Elakkya (21760439)

“…Under salt and osmotic stress, A. chroococcum W5 metabolomic profiling revealed adaptive responses, including elevated levels of osmoprotectants (proline, glycerol) and oxidative stress markers such as 2-hydroxyglutarate, while putrescine and glycine decreased.…”

Table 4_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xls by Guilin Ren (18720749)

“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”

Table 4_Comparative genomics and metabolomics reveal phytohormone production, nutrient acquisition, and osmotic stress tolerance in Azotobacter chroococcum W5.xlsx by M. Elakkya (21760439)

“…Under salt and osmotic stress, A. chroococcum W5 metabolomic profiling revealed adaptive responses, including elevated levels of osmoprotectants (proline, glycerol) and oxidative stress markers such as 2-hydroxyglutarate, while putrescine and glycine decreased.…”

Image 4_Comparative genomics and metabolomics reveal phytohormone production, nutrient acquisition, and osmotic stress tolerance in Azotobacter chroococcum W5.tif by M. Elakkya (21760439)

“…Under salt and osmotic stress, A. chroococcum W5 metabolomic profiling revealed adaptive responses, including elevated levels of osmoprotectants (proline, glycerol) and oxidative stress markers such as 2-hydroxyglutarate, while putrescine and glycine decreased.…”

Table 3_Comparative genomics and metabolomics reveal phytohormone production, nutrient acquisition, and osmotic stress tolerance in Azotobacter chroococcum W5.xlsx by M. Elakkya (21760439)

“…Under salt and osmotic stress, A. chroococcum W5 metabolomic profiling revealed adaptive responses, including elevated levels of osmoprotectants (proline, glycerol) and oxidative stress markers such as 2-hydroxyglutarate, while putrescine and glycine decreased.…”

Table 2_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx by Guilin Ren (18720749)

“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”

Image 3_Comparative genomics and metabolomics reveal phytohormone production, nutrient acquisition, and osmotic stress tolerance in Azotobacter chroococcum W5.tif by M. Elakkya (21760439)

“…Under salt and osmotic stress, A. chroococcum W5 metabolomic profiling revealed adaptive responses, including elevated levels of osmoprotectants (proline, glycerol) and oxidative stress markers such as 2-hydroxyglutarate, while putrescine and glycine decreased.…”

Table 6_Comparative genomics and metabolomics reveal phytohormone production, nutrient acquisition, and osmotic stress tolerance in Azotobacter chroococcum W5.docx by M. Elakkya (21760439)

“…Under salt and osmotic stress, A. chroococcum W5 metabolomic profiling revealed adaptive responses, including elevated levels of osmoprotectants (proline, glycerol) and oxidative stress markers such as 2-hydroxyglutarate, while putrescine and glycine decreased.…”

Table 7_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx by Guilin Ren (18720749)

“…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”

Table 2_Comparative genomics and metabolomics reveal phytohormone production, nutrient acquisition, and osmotic stress tolerance in Azotobacter chroococcum W5.docx by M. Elakkya (21760439)

“…Under salt and osmotic stress, A. chroococcum W5 metabolomic profiling revealed adaptive responses, including elevated levels of osmoprotectants (proline, glycerol) and oxidative stress markers such as 2-hydroxyglutarate, while putrescine and glycine decreased.…”